LeMaitre Vascular announced strong second-quarter 2025 financial results, with net sales reaching $64.2 million, a 15% increase from Q2 2024, surpassing analyst expectations. This growth was primarily driven by catheters, which saw a 27% increase, and grafts, up 19%. Both price increases, contributing 8% to sales growth, and unit increases, adding 7%, were key factors in the robust performance.
Geographically, EMEA sales surged by 23%, Americas sales increased 12%, and Asia Pacific sales also grew by 12%, indicating broad international strength. The company's gross margin expanded to 70.0%, up from 68.9% in Q2 2024, due to higher average selling prices and manufacturing efficiencies. Operating income rose 12% to $16.1 million, and diluted earnings per share increased 16% to $0.60, both exceeding estimates.
Following these strong results, LeMaitre Vascular further raised its full-year 2025 guidance, now expecting reported sales of $245 million and organic growth of 13%. The updated outlook includes a gross margin of 69.6%, operating income of $57.7 million, and diluted earnings per share of $2.16 at the midpoint. Chairman and CEO George LeMaitre highlighted that the Artegraft OUS launch is ahead of plan, contributing to the increased top- and bottom-line guidance for the year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.